Debio 0123: Clinical Trials

3 terminated, 1 recruiting. 4 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	4	Terminated 3, Recruiting 1
Phase 2	1	Recruiting 1

Follow Debio 0123: new trials by email Literature Review of Debio 0123 trials Research Report on Debio 0123

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma Debio 0123, Temozolomide, Radiotherapy - Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III	Phase 1 / Phase 2	Recruiting	Debiopharm International SA	116	2023-05-15	2026-09-22
Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy Debio 0123, Etoposide, Carboplatin - Small Cell Lung Cancer Recurrent	Phase 1	Terminated	Debiopharm International SA	34	2023-05-02	2026-05-04
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors Debio 0123 - Advanced Solid Tumors	Phase 1	Terminated	Debiopharm International SA	93	2021-11-05	2026-06-23
Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors Debio 0123, Carboplatin - Advanced Solid Tumors	Phase 1	Terminated	Debiopharm International SA	76	2019-07-30	2025-12-05

Conditions studied

Astrocytoma (1)  ·  Glioblastoma (1)  ·  Lymphoma, Follicular (1)  ·  Recurrence (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

Debiopharm International SA (4)

Countries

Spain (4)  ·  United States (3)  ·  Switzerland (2)  ·  Netherlands (1)

NIH funding

2023 (1)